Literature DB >> 27167291

Inverse treatment planning for spinal robotic radiosurgery: an international multi-institutional benchmark trial.

Oliver Blanck1, Lei Wang, Wolfgang Baus, Jimm Grimm, Thomas Lacornerie, Joakim Nilsson, Sergii Luchkovskyi, Isabel Palazon Cano, Zhenyu Shou, Myriam Ayadi, Harald Treuer, Romain Viard, Frank-Andre Siebert, Mark K H Chan, Guido Hildebrandt, Jürgen Dunst, Detlef Imhoff, Stefan Wurster, Robert Wolff, Pantaleo Romanelli, Eric Lartigau, Robert Semrau, Scott G Soltys, Achim Schweikard.   

Abstract

Stereotactic radiosurgery (SRS) is the accurate, conformal delivery of high-dose radiation to well-defined targets while minimizing normal structure doses via steep dose gradients. While inverse treatment planning (ITP) with computerized optimization algorithms are routine, many aspects of the planning process remain user-dependent. We performed an international, multi-institutional benchmark trial to study planning variability and to analyze preferable ITP practice for spinal robotic radiosurgery. 10 SRS treatment plans were generated for a complex-shaped spinal metastasis with 21 Gy in 3 fractions and tight constraints for spinal cord (V14Gy < 2 cc, V18Gy < 0.1 cc) and target (coverage > 95%). The resulting plans were rated on a scale from 1 to 4 (excellent-poor) in five categories (constraint compliance, optimization goals, low-dose regions, ITP complexity, and clinical acceptability) by a blinded review panel. Additionally, the plans were mathemati-cally rated based on plan indices (critical structure and target doses, conformity, monitor units, normal tissue complication probability, and treatment time) and compared to the human rankings. The treatment plans and the reviewers' rankings varied substantially among the participating centers. The average mean overall rank was 2.4 (1.2-4.0) and 8/10 plans were rated excellent in at least one category by at least one reviewer. The mathematical rankings agreed with the mean overall human rankings in 9/10 cases pointing toward the possibility for sole mathematical plan quality comparison. The final rankings revealed that a plan with a well-balanced trade-off among all planning objectives was preferred for treatment by most par-ticipants, reviewers, and the mathematical ranking system. Furthermore, this plan was generated with simple planning techniques. Our multi-institutional planning study found wide variability in ITP approaches for spinal robotic radiosurgery. The participants', reviewers', and mathematical match on preferable treatment plans and ITP techniques indicate that agreement on treatment planning and plan quality can be reached for spinal robotic radiosurgery.

Entities:  

Mesh:

Year:  2016        PMID: 27167291      PMCID: PMC5690905          DOI: 10.1120/jacmp.v17i3.6151

Source DB:  PubMed          Journal:  J Appl Clin Med Phys        ISSN: 1526-9914            Impact factor:   2.102


I. INTRODUCTION

Hallmarks of stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT) include the accurate, conformal delivery of high‐dose radiation to targets while minimizing normal tissue irradiation via precise target localization and steep dose gradients through multiple beam directions. , Most SRS/SBRT delivery systems today incorporate complex target localization and motion compensation strategies , and allow for nearly limitless possibilities for beam shapes, orientations, motion, and intensities, making it cumbersome, if not impossible, to create forward‐planned treatment plans in routine practice. Therefore, almost all treatment planning systems use inverse treatment planning (ITP) with a variety of optimization algorithms. , , , , Recently, multicriteria optimization , to accommodate different clinical preferences and conflicting optimization objectives (e.g., maximizing tumor coverage while minimizing normal tissue doses) have been added to the increasing complexity of computer‐aided treatment planning. Yet, not all possible beam configurations can be simulated, due to computational and temporal constraints. Therefore, the quality of treatment planning remains user‐dependent as manual preselection of optimization and beam parameters are generally required. , Additionally, the background training and experience of the treatment planner can vary significantly. A general quality measure for the treatment planning process or the treatment planner itself does not exist and a best practice guideline is largely missing for all radiotherapy systems in clinical practice. To make a first step to overcome this shortage, we performed an international, multi‐institutional treatment planning benchmark trial to analyze treatment planning variability and to analyze best practice for treatment planning for spinal robotic radiosurgery with the CyberKnife (Accuray Incorporated, Sunnyvale, CA).

II. MATERIALS AND METHODS

A. Treatment planning for robotic radiosurgery

Treatment planning for CyberKnife with the MultiPlan Treatment Planning System (version 4.5) (Accuray) is based on inverse planning using linear optimization. In the first step, 500‐1500 beams per manually selected cylindrical beam size (5‐60 mm) are randomly oriented toward target surface points from approximately 120‐180 precalibrated linear accelerator positions around the patient couch, resulting in 1500‐6000 noncoplanar nonisocentric beams. Alternatively, a strictly isocentric beam arrangement can be generated, which is rarely used for complex‐shaped targets as it limits the flexibility during optimization. In the second step, a large inequality matrix is generated based on the calculated beam dose coefficients of each voxel of the discretized contours and manually predefined dose constraints. A weighted cost function representing the planning objectives is then minimized, using linear programming (LPSolve, SourceForge or CPLEX, IBM ILOG), to determine the optimal monitor unit (MU) for each beam, which generally results in 50‐350 treatment beams, depending on case complexity and beam size selection. Previously the whole cost function was minimized simultaneously using manually set weights for the individual objectives (MultiPlan versions prior to version 3.0). Sequential Multi‐Objective Optimization (SMOO; introduced in 2008 with MultiPlan version 3.0) minimizes each term of the cost function in a stepwise procedure in which the result of each step becomes a constraint in the next step subtracted by a manually set relaxation value. Therefore, SMOO facilitates the exploration of maximum trade‐offs between different objectives like maximal target coverage, minimal critical structure dose, maximal dose conformity using shell structures or minimal total monitor units. Dose‐volume optimization, (pseudo) dose‐volume‐constraints, resampling, and reoptimization with removed low MU beams further added to the flexibility during this interactive treatment planning process. Initial studies with SMOO and multiple collimators demonstrated that superior plan quality was achievable over simultaneous optimization, but SMOO also introduced much more user‐dependent variability in planning, with possible resultant variability in treatment plan quality.

B. Treatment planning benchmark

A single, complex‐shaped, recurrent, previously irradiated spinal metastasis (see Fig. 1) was selected for this study. The planning target volume (PTV) was 40.2 cc (maximum dimension , median beam's eye view segment size approx. 2 cm), located in the lower thoracic region (T11/T12) and close to the kidneys. All volumes of interest were defined on CT/MR fusion images. Given the prior fractionated irradiation to the spinal cord, a conservative target dose of 21 Gy in 3 fractions with strict limits for the spinal cord (, ) was chosen. Higher target doses of 27‐30 Gy in 3 fractions may have been led to higher local control; , however, the given limitations for the spinal cord due to multiple preirradiations did not allow a higher dose for this patient. A secondary defined constraint was the dose to the kidney ().
Figure 1

Axial, sagittal, and coronal view of the planning target volume (red), spinal cord (yellow), and kidneys (purple) for the spinal benchmark case.

Axial, sagittal, and coronal view of the planning target volume (red), spinal cord (yellow), and kidneys (purple) for the spinal benchmark case. The planning objectives were a) not to exceed the spinal cord limits and to achieve at least 95% of the prescribed dose (21 Gy) covering the PTV, and b) to maximize conformity of the prescribed isodose to the PTV (due to previous irradiation and risk of fracture outside the target area) and to minimize total monitor units and treatment time alike (due to back pain of the patient). Objectives not explicitly mentioned to the participants were: to optimize PTV minimum dose, spinal cord, kidney, and skin maximum doses and dose to the healthy tissue surrounding the PTV. Ten dedicated medical physicists or dosimetrists from eight CyberKnife centers volunteered to generate a clinically acceptable treatment plan based on the above planning objectives according to their standard code of practice. Treatment planning was performed on a single, dedicated, remotely accessible MultiPlan station within a 24‐hr timeslot to simulate realistic clinical practice. All participants were blinded to other participants' treatment plans, which was ensured by anonymization and computer log file monitoring during the study.

C. Review panel ranking

All 10 anonymous cases were then reviewed by an independent review panel of three neurosurgeons, five radiation oncologists, and two medical physicists who did not participate in the study. Each review panel member rated the 10 cases based on a scale from 1 to 4, with 1 being good or excellent, 2 being average, 3 being below average, and 4 being poor for a) meeting the main clinical objectives (spinal cord and , 95% PTV coverage), b) optimizing secondary objectives (conformity, monitor units, treatment time), and c) optimizing objectives not explicitly mentioned (PTV , spinal cord , kidney , skin , dose gradient). The physicists also rated d) the complexity of the ITP process (tuning structures, collimator selection, constraint selection, shell structures, optimization script), and the clinicians rated e) the clinical acceptability of the treatment plan (treatment complexity, potential treatment flaws, dose distribution, trade‐offs between conflicting objectives). Each final plan ranking was calculated based on the sum of the ratings of the individual categories (A‐E) and a normal distribution (bell curve) of the scale mentioned above (1‐4) over the lowest and highest sum.

D. Mathematical ranking

In addition to the empirical ranking by the review panel, we also performed a mathematical ranking based on plan indices to explore potential automated plan quality comparison. We used the secondary plan review software ARTIVIEW (AQUILAB, Loos les Lille, France) to calculate all plan indices based on the original plans. On the basis of the planning objectives and the review panel ranking, the following indices were analyzed in three categories: A) spinal cord and and PTV coverage at 21 Gy (prescription dose), B) conformity index (ratio between the total volume receiving 21 Gy and the PTV), total monitor units, and the estimated treatment time (includes patient setup, robot motion, and beam‐on time), and C) PTV , spinal cord , kidney , 5 mm skin , and volume10 cm (the volume receiving 10 Gy in the 10 cm volume surrounding the PTV). Additionally, for Category A, we calculated a potential represcription dose for the PTV based on the normal tissue complication probability (NTCP) for the spinal cord. To estimate the spinal cord myelopathy NTCP, we used the DVH Evaluator (DiversiLabs, Biomérieux, Durham, NC) and published literature for spinal cord tolerances , resulting in spinal cord limits of and . We then represcribed the dose so that the spinal cord was lower than or equal to 0.1 cc and the spinal cord was lower than or equal to 1 cc and noted the PTV , the dose received by 95% of the PTV. Without this step, each plan has a different PTV coverage dose and a different NTCP risk level, making comparisons more complex. Therefore we essentially hold NTCP fixed for all cases, and represcribed each plan to the corresponding highest possible to compare tumor dose more clearly. Finally, we rated each index based on the same scale (1‐4) mentioned above, using the normal distribution (bell curve) of the best and the worst results for that index. The final plan ranking was also calculated as above.

III. RESULTS

A. Treatment planning approaches

The treatment planning approaches varied substantially among various participating CyberKnife centers and their designated treatment planner (TP) for this study (Table 1). The optimization script also varied substantially among the TP ranging from 1 to 17 SMOO steps (median 5 steps). Six TP (60%) used dose‐volume constraints and only five TP explicitly constrained the kidney maximum dose. Three TP optimized minimum PTV dose, while the others optimized PTV coverage in the first step, with only one TP using dose‐volume optimization. After PTV optimization, six TP (60%) focused on spinal cord optimization, while two (20%) focused on dose falloff by reducing the shell structures' maximum doses. Five TP (50%) optimized at the end the monitor units which did not adhere to the initial maximum MU limits. Only one TP (10%) used only one optimization step and manually adjusted critical organs, tuning shells, and MU constraints in multiple reoptimization iterations (TP case 10). For beam and monitor unit (MU) constraints, four TP (40%) explicitly limited the maximum MU, while three TP (30%) limited the MU through collimator selection, and three TP (30%) relied solely on artificial shell structures to limit the skin and hot spot doses. Collimator sizes between 10‐25 mm were generally preferred for this treatment agreeing with the median beam's eye view PTV segment size, with overall median collimator sizes per TP of 20 mm (min 12.5 mm, max 40 mm). The Iris (Accuray Inc.) variable aperture collimator was used by five TP (50%), while the other five noted that they did not use the Iris collimator clinically.
Table 1

Treatment approaches of the different participating centers.

Case
C 1 C 2 C 3 C 4 C 5 C 6 C 7 C 8 C 9 C 10
Plan Setup
      Beam Blockn/an/aArmsArmsn/an/an/an/an/an/a
      Max MU/Noden/a6007508501400550900n/a900925
      Max MU/Beam600300735500450290400300450425
      Max Total MU3600040000n/an/an/an/an/an/a4500041000
      Shell Structures4384322234
      Tuning Structuresn/an/an/a2n/a1n/a1n/an/a
      Collimator Iris/FixedIrisIrisFixedFixedIrisFixedFixedFixedIrisIris
        (sizes in mm)7.5‐2512.5‐30/407.5‐25/4010/15/207.5/10/15‐2512.5/257.5/15/3025/40/607.5‐2010/15/20/35
      Median Coll. Size (mm)15.025.020.015.015.020.020.040.012.520.0
Optimization
      Spinal Cord Max (cGy)1820160016681750175017501740200018001850
      Volume Constraint (cc)n/an/an/a V14<1.7 n/a V14<2 V14<1.8 V18<0.1 V14<2 V14.8<2
      Kidney ConstraintsNYYNNYNNYY
      OCO/OMI /DVLOCOOCOOMI/COOMI/COOCOOCOOCOOMI/COOCODVL
      OMA/OME/DVUOMEDVUOMAOMEn/an/aOMAn/aOMAn/a
      OME Kidney Y/NNYYYNNNNNN
      Shell Structures2082 Tuning312030
      OMU Y/NNYYNYYYNNN
      Optimization Steps45178535251

OCO = optimize coverage; OMI/CO = Optimize Min Dose first and second Optimize Coverage; DVL = dose volume optimization; OMA = optimize max dose; OME = optimize mean dose; DVU = dose‐volume optimization; OMU = optimize monitor units; Y = yes; N = no; n/a = not assigned.

Treatment approaches of the different participating centers. OCO = optimize coverage; OMI/CO = Optimize Min Dose first and second Optimize Coverage; DVL = dose volume optimization; OMA = optimize max dose; OME = optimize mean dose; DVU = dose‐volume optimization; OMU = optimize monitor units; Y = yes; N = no; n/a = not assigned.

B. Resulting treatment plans

As with the treatment planning approaches, the resulting treatment plans also varied substantially among the participating CyberKnife centers (Table 2). Examples are shown in Fig. 2. Eight TP (80%) reached the minimum required coverage of 95% in the PTV while the prescription isodose levels ranged from 65%–82%, allowing maximum doses in the PTV between 25.6‐32.3 Gy. The conformity index (CI) ranged from 1.5 to 2.3 (mean 1.7), resulting mainly from optimization of the tuning and shell structures and not from the collimator selection. For the critical organs, the strict maximum spinal cord volume constraints were exceeded by three TP (30%) and the maximum kidney limit by one TP (10%). The maximum spinal cord dose ranged from 17.1‐20.7 Gy (mean 18.8 Gy) and the maximum kidney dose ranged from 10.6‐22.3 Gy (mean 18.6 Gy). The Volume10 cm ranged 233‐424 cc (mean 313 cc). The number of resulting treatment beams and beam directions (nodes) ranged from 118‐232 (mean 180) and 48‐92 (mean 70), respectively. The number of nodes and the MU per node limitation did not directly correlate with the skin dose; however, the highest skin dose (19 Gy) was noted to be with the lowest number of nodes and a high MU per node allowance (case 5). The final plan MU varied between 29,507 and 74,276 which did not directly correlate with MU optimization or initial maximum MU limitation. The final estimated treatment time ranged from 39 to 89 min per fraction (mean 56), which included 5 min per fraction for patient setup and alignment.
Table 2

Final treatment plans of the participating centers.

Case
Results C 1 C 2 C 3 C 4 C 5 C 6 C 7 C 8 C 9 C 10
Beams118209226228187232161139171132
Nodes64928982488553488259
PTV Coverage (%)96.391.495.795.495.995.295.192.295.096.0
Spinal Cord V14Gy (cc)2.02.02.42.62.01.71.93.11.61.9
Spinal Cord V18Gy (cc)0.00.00.10.20.00.00.10.30.10.0
Re‐Rx Dose (Gy)21.822.020.820.322.521.921.119.021.422.2
Conformity Index1.81.51.81.51.71.71.72.31.81.6
Monitor Units (MU)34,13038,85662,37874,27656,35743,10642,55829,50743,92338,936
Treatment Time a (min)39528972516555444942
PTV Dmin (Gy)17.516.916.817.318.116.216.617.714.716.3
Spinal Cord Dmax (Gy)18.417.118.920.718.018.418.919.319.718.3
Kidney Dmax (Gy)22.319.410.618.320.418.919.621.920.414.2
Skin5mm Dmax (Gy)10.010.011.015.019.010.015.015.015.012.0
Volume10cm V10Gy (cc)330367238362352249265424313233

Treatment time is measured per fraction including setup and robot motion time.

PTV = planning target volume; ; Volume10cm = 10 cm volume surrounding the PTV; Re‐Rx Dose = Max PTV D95% (Gy) subject to NTCP limits.

Figure 2

Examples of final treatment plans: (a) Case 2 with good conformity, but low coverage (clinically acceptable); (b) Case 4 with good conformity, but high spinal cord dose (clinically not acceptable); (c) Case 8 with low monitor units and treatment time, but high spinal cord dose and low conformity;(d) Case 10 with balanced trade‐off between spinal cord doses, coverage, conformity, and monitor units.

Final treatment plans of the participating centers. Treatment time is measured per fraction including setup and robot motion time. PTV = planning target volume; ; Volume10cm = 10 cm volume surrounding the PTV; Re‐Rx Dose = Max PTV D95% (Gy) subject to NTCP limits. Examples of final treatment plans: (a) Case 2 with good conformity, but low coverage (clinically acceptable); (b) Case 4 with good conformity, but high spinal cord dose (clinically not acceptable); (c) Case 8 with low monitor units and treatment time, but high spinal cord dose and low conformity;(d) Case 10 with balanced trade‐off between spinal cord doses, coverage, conformity, and monitor units. Similar to the variations in the treatment planning approaches and the resulting treatment plans, the reviewers varied substantially in their individual category and final plan ranking (Table 3). Four plans received a high rating (1) and also a low rating (4) by at least one reviewer and two plans each received ratings between 1‐3 and 2‐4, respectively, demonstrating the different clinical priorities of different participating reviewers. Nevertheless, the review panel did agree on case 8, which was ranked low (4) and also had the highest spinal cord doses, and on case 10, which was ranked high (1‐2) and had a balanced mix of low monitor units, spinal cord doses, and high conformity and coverage. On summing up the individual reviewer rankings and generating an overall ranking (1‐4), two plans (20%) were ranked in the excellent category (1), four plans (40%) in the average category (2), two plans (20%) in the below average category (3), and two plans in the poor category (4). The three plans that did not obey the strict spinal cord limits also received poor overall ranking (rank sum ) and were deemed not acceptable for treatment.
Table 3

Reviewer ranking of the final treatment plans (, , , ).

Human Ranking Reviewer Case
C 1 C 2 C 3 C 4 C 5 C 6 C 7 C 8 C 9 C 10
RV 11343212412
RV 22233412431
RV 31134212432
RV 42244212421
RV 52234222441
RV 64324222421
RV 73333111421
RV 81142243441
RV 91134211431
RV 10233321344 1
Min1122111411
Max4344443442
Mean1.92.13.23.42.11.52.04.02.81.2
Median2.02.03.03.52.01.02.04.03.01.0
SD.1.00.90.60.70.71.00.70.01.00.4
Rank Sum19213234211520402812
Final Rank2234212431
Reviewer ranking of the final treatment plans (, , , ). The mathematical ranking demonstrated similar results to the mean overall reviewer ranking (Table 4), which potentially enables this mathematical formula to be used for overall quality comparison of treatment plans. Nine out of 10 (90%) final mathematical rankings agreed with the overall review panel ranking. Weighting the spinal cord dosimetry by a factor of 2 did not change the ranking of the plans. A negative difference (worse mathematical than reviewer ranking) was found in case 7, which could be due to the fact this plan had no visible negative flaw (e.g., high spinal cord doses or low conformity), but the resulting indices were mostly below the average compared to the other nine plans. The mathematical ranking sum was, however, not a direct indicator for the clinical acceptability of the treatment plan, as case 7 had a higher overall rank than case 3, but had the 4th lowest overall rank in the review panel ranking.
Table 4

Mathematical ranking of the treatment plans ((, , , )).

Mathematical Ranking Index Case
C 1 C 2 C 3 C 4 C 5 C 6 C 7 C 8 C 9 C 10
PTV Coverage1412122421
Cord V14Gy (cc) 2234212412
Cord V18Gy (cc) 1134113421
Re‐Rx Dose2133113421
Conformity Index3131223432
Monitor Units1244322122
Treatment Time a 1243232121
PTV Dmin2222133143
Spinal Cord Dmax2134223332
Kidney Dmax4312433441
Skin 5 mm Dmax3213413321
Volume10cm V10Gy 3413311421
Rank Sum (nonweighted)25252935262230372918
Final Rank2234213431
Weighted Sum (factor 2 on spinal cord)28283543292435453221
Final Weighted Rank2234213431

Treatment time in measured per fraction including setup and robot motion time.

PTV = planning target volume; ; Volume10cm = 10 cm volume surrounding the PTV; Re‐Rx Dose = Max PTV D95% (Gy) subject to NTCP limits.

Mathematical ranking of the treatment plans ((, , , )). Treatment time in measured per fraction including setup and robot motion time. PTV = planning target volume; ; Volume10cm = 10 cm volume surrounding the PTV; Re‐Rx Dose = Max PTV D95% (Gy) subject to NTCP limits.

E. Study agreement

Based on the results of this study, agreement was found by the study participants for the following points: A well‐balanced treatment plan in terms of all plan indices is generally preferable over treatment plans with extreme quality in only a few categories (e.g., case 10 and case 6 vs. case 3 and 4 with very low surrounding dose and high conformity, but high spinal cord dose and MU as trade‐off) as long as any strict critical structure limits are not violated. Well‐balanced trade‐offs between higher and lower prioritized objectives may be made based on the treatment intent (e.g., curative, palliative, reirradiation). Producing high‐quality treatment plans for complex tumor shapes may not require complex treatment planning with multiple tuning structures or lengthy optimization scripts (e.g., case 10). Due to the sequential steps implementation of SMOO in MultiPlan (version 4.5), the optimizer could be stuck on a local optimum after a few steps.11 The use of short and simple optimization scripts and/or manual adjustment of the constraints combined with iterative optimization with different scripts can help to explore the various trade‐offs of the planning constraints and goals in order to create a well‐balanced treatment plan for a specific case. Regardless of the distance to the target area, critical structures should in general be dosimetrically optimized according to the as‐low‐as‐reasonably‐achievable (ALARA) principle (i.e., the minimization of critical structure maximum doses is advised) if this is not detrimental to the plan quality (e.g., case 10 where the maximum kidney dose was limited without impairing the spine dose or target coverage). Generally, it was agreed upon by the study participants that good clinical practice is the blocking of sensitive critical structures far away from the target area (e.g., blocking beams incidental to the eyes during general cranial radiosurgery). The skin dose and potential hot spots outside the direct proximity of the target should be evaluated after the mandatory dose calculation in the full planning CT dose grid. During optimization in small dose grids, the skin and hot spot dose can be controlled using MU per Node constraints (e.g., 200‐350 MU per node per fraction) or larger tuning shell volumes (e.g., 3‐5 cm surrounding the PTV due to the 6 MV beam buildup). Higher inhomogeneity and therefore higher maximum dose to the PTV does not automatically lead to better dose gradients or better treatment plan quality (e.g., case 4 and 7). If clinically justified, a certain degree of inhomogeneity to the target dose is unlikely to impair the plan quality, as long as the maximum‐dose regions are generally kept within the central gross tumor volume. The Iris variable‐aperture collimator may not necessarily lead to better dosimetric plan quality (e.g., case 6 vs. 10 with similar dosimetry). However, the Iris collimator can reduce treatment time and allows easier collimator selection, potentially reducing the overall treatment planning time. Small collimator sizes, high number of beams, and high monitor units do not always and automatically lead to high dose conformity and high treatment plan quality even when treatment time is not evaluated (e.g., case 4 vs. case 10). Allowing beams crossing the arms is acceptable if the arms are fully visible in the planning CT and if their repositioning during treatment is reproducible with confidence. Blocking incidental beams to the arms may reduce plan quality due to beam angle limitations (e.g., case 3 and 4).

IV. DISCUSSION

This international benchmark study for robotic radiosurgery demonstrated various approaches to inverse treatment planning and plan quality preferences throughout a range of CyberKnife centers. Nevertheless, agreement on plan quality and basic approaches to treatment planning could be reached using an independent review panel and plan quality ranking functions. While our planning guidelines are specific for spinal robotic radiosurgery, our presented method may also be useful for providing reference information for quality improvement and quality control and enabling further investigation of homogenization and standardization of radiotherapy and radiosurgery treatment planning. While contouring guidelines have been widely accepted (e.g., for spine SBRT ) and treatment planning studies using different radiation devices or treatment delivery benchmark studies (e.g., for spine SBRT ) are common, the quality of radiotherapy treatment planning has been only rarely investigated and often only on a national level. , , , , Since treatment planning is strongly user‐dependent and quality control of treatment planning is largely lacking, this study was our first approach to provide a method for quality comparison and to define planning guidelines, in our first case for spinal robotic radiosurgery. In the selection of the participants, as there are now more than 300 installed CyberKnife units worldwide, we tried to find a balanced mix between very experienced ( yrs) and rather new users ( yr) to the CyberKnife. However, the experience of the user did not reflect in the resulting plan quality — for example, the planner of case 6 (2nd in ranking) did not have access to MultiPlan version 4.5 before this study. From the results of our study, it also became clear that treatment plans generated with simple optimization scripts (i.e., case 6 or case 10) may yield better results than those with complex scripts and multiple tuning structures. Since a very simple treatment planning technique yielded good results, our planning guidelines may also be valid for simple targets and other indications, requiring further validation. Practical guidelines for robotic radiosurgery treatment planning can be found in Appendix A. A simple approach to CyberKnife treatment planning could be to start with known critical structure limitations as hard constraints, maximize the target coverage in the first step and minimize the dose to the tuning shell structures for dose conformity (e.g., planning for case 5 and 6). This simple approach can already lead to high‐quality treatment plans. Furthermore, the resulting shell doses could be used as constraints in a second optimization script in order to minimize the dose to the critical structures (e.g., planning for case 2). It may be noted that some specific optimization steps (e.g., minimum volume dose optimization) could potentially yield inferior results compared to others especially with nearby critical structures (i.e., planning for cases 3, 4, and 8 with the highest spinal cord doses). To still archive acceptable results while using the minimum volume dose constraint, the goal relaxation value needs to be large enough to warrant the competition between the different objectives in those cases. Another approach to CyberKnife treatment planning could be to manually derive the tuning shell and critical structure doses by subsequently reducing the maximum and volume constraints until the target receives coverage (e.g., planning of case 10). This iterative optimization technique is the basis of the sequential multiobjective optimization. Yet, since the implementation of SMOO in MultiPlan (since version 3.0), plan optimization scripts are used more commonly. Regardless of the type of optimization, skin entry doses and hot spots outside the target should be controlled as to avoid severe skin or organ reactions. This is not an easy task with the CyberKnife due to the many beam directions and the generally small optimization grids used during planning. A dose calculation covering all beam entry spots is strongly recommended, and actions to limit the skin and hot spot dose during optimization are proposed in our planning guidelines. Furthermore, it is well known that different treatment planning protocols can lead to large differences in organ‐at‐risk sparing, , and our study also highlighted those differences when comparing the kidney maximum doses. In contrast to other studies, we advise that treatment planning should be generally based on the ALARA (as‐low‐as‐reasonably‐achievable) principle rather than on implementing stricter constraints for critical structures. Sensitive critical structures farther from the target may as well be blocked by beam intersection altogether to ensure the ALARA principle and to avoid multiple replanning steps. The reviewer ranking of the plans revealed that well‐balanced treatment plans were preferred for treatment over plans with extreme quality in only a few categories. It should be noted that a plan exceeding the spinal cord constraints (i.e., case 3, 4, and 8) would have not been accepted for treatment. These plans were, therefore, rated low in Category A (main clinical objectives) and Category E (clinical assessment), providing a certain weighting in the favor of low spinal cord doses. Indeed, the plans exceeding the spinal cord limit received the lowest mean overall ranking. Because a large review panel quality assessment is not always available in general routine practice, we also wished to provide a mathematical measure for plan quality assessment. This approach to determine the best treatment plan has been investigated, , , , , but does not yet encompass the multidimensional complexity of radiosurgery plan quality and the preferences of the treating clinicians. Our simple mathematical ranking system generated the same category as the expert review panel in 9 out of 10 cases. The inclusion of multiple indices for the spinal cord (, , ) also provided a similar weighting compared to the review panel ranking in the favor of low spinal cord doses. Nevertheless, caution is advised when using this formula, as severe treatment flaws (e.g., unacceptably high spinal cord doses in case 3) may be masked by high scores in other indices. Penalties or a weighting factor (Table 4) on certain aspects of the treatment plan based on clinical preferences may make this simple formula more robust and adaptable to other entities and a larger number of participants, both of which are subjects for further investigation. Limitations of our study are the number of cases and the number of participants and reviewers , and we are aware that both the guidelines and the ranking system would need to be validated in larger cases series to be applicable for spine or robotic radiosurgery in general. Nevertheless, this is the first study and attempt at standardization of treatment plan and planning quality for robotic radiosurgery. We selected a single complex‐shaped tumor surrounding a critical structure to demonstrate that, even for such a challenging case, simple planning methods can lead to high‐quality treatment plans, allowing the planning guidelines to be potentially applicable to simple cases, as well. One may also argue that the whole spine could have been included in the PTV and the dose chosen for this treatment may be low for spine SBRT, , but as noted earlier, the patient had received preirradiation to this area limiting the spinal cord dose significantly. We believe that across the 10 treatment plans, the range of treatment plan qualities for this case was reasonably covered. Further incorporation of 17 more treatment plans into the mathematical ranking, all created by independent planner without knowledge of the results of this study, did not alter the ranking significantly nor did it change any point of the planning guidelines. However, we cannot state with absolute certainty that the treatment planning approach or the quality of the best‐ranked treatment plan in this study (i.e., case 10) is the best achievable for this patient. Further improvements to robotic radiosurgery optimization of spine SBRT have already been demonstrated , , and the new InCise (Accuray Inc.) multileaf collimator for the CyberKnife may further improve plan quality. Nevertheless, our study demonstrates that a best practice approach to CyberKnife treatment planning is feasible, and further cases and a measure for treatment planning quality improvement are under investigation.

V. CONCLUSIONS

This multi‐institutional study illustrates different inverse treatment planning approaches and treatment preferences for spinal robotic radiosurgery. Despite their wide variation in experience, training, and clinical preferences, the participants', reviewers', and the mathematical formula's agreement on the preferable treatment plan quality and on the inverse treatment planning techniques indicates that agreement on treatment planning and plan quality can be reached for spinal robotic radiosurgery. The provided data and method for benchmarking and the planning guidelines could potentially improve the consistency of treatment planning for robotic radiosurgery in the future.

ACKNOWLEDGMENTS

The authors would like to thank Etienne Lessard (Accuray) for his support in this study and Mikail Gezginci (Accuray) for his helpful remarks. Centre Oscar Lambret has a collaboration agreement with Accuray. Jimm Grimm has a patent for the DVH Evaluator issued. Otherwise, the authors declare that they have no competing interests.

COPYRIGHT

This work is licensed under a Creative Commons Attribution 4.0 International License. Supplementary Material Click here for additional data file. Supplementary Material Click here for additional data file. Supplementary Material Click here for additional data file.
  41 in total

1.  Inverse planning for four-dimensional (4D) volumetric modulated arc therapy.

Authors:  Yunzhi Ma; Daniel Chang; Paul Keall; Yiaoqin Xie; Jae-yoon Park; Tae-suk Suh; Lei Xing
Journal:  Med Phys       Date:  2010-11       Impact factor: 4.071

2.  Multicriteria optimization of the spatial dose distribution.

Authors:  Alexander Schlaefer; Tiberiu Viulet; Alexander Muacevic; Christoph Fürweger
Journal:  Med Phys       Date:  2013-12       Impact factor: 4.071

3.  Spine stereotactic body radiation therapy plans: Achieving dose coverage, conformity, and dose falloff.

Authors:  Linda X Hong; Viswanathan Shankar; Jin Shen; Hsiang-Chi Kuo; Dinesh Mynampati; Ravindra Yaparpalvi; Lee Goddard; Amar Basavatia; Jana Fox; Madhur Garg; Shalom Kalnicki; Wolfgang A Tomé
Journal:  Med Dosim       Date:  2014-12-11       Impact factor: 1.482

4.  Different treatment planning protocols can lead to large differences in organ at risk sparing.

Authors:  Jim P Tol; Max Dahele; Patricia Doornaert; Ben J Slotman; Wilko F A R Verbakel
Journal:  Radiother Oncol       Date:  2014-11-04       Impact factor: 6.280

Review 5.  Modern radiosurgery equipment for treating brain metastases.

Authors:  Hyun-Tai Chung; Dong Gyu Kim
Journal:  Prog Neurol Surg       Date:  2012-01-06

6.  Cerebral radiation surgery using moving field irradiation at a linear accelerator facility.

Authors:  G H Hartmann; W Schlegel; V Sturm; B Kober; O Pastyr; W J Lorenz
Journal:  Int J Radiat Oncol Biol Phys       Date:  1985-06       Impact factor: 7.038

7.  Stereotactic radiosurgery utilizing a linear accelerator.

Authors:  F Colombo; A Benedetti; F Pozza; A Zanardo; R C Avanzo; G Chierego; C Marchetti
Journal:  Appl Neurophysiol       Date:  1985

8.  Single-session and multisession CyberKnife radiosurgery for spine metastases-University of Pittsburgh and Georgetown University experience.

Authors:  Dwight E Heron; Malolan S Rajagopalan; Brandon Stone; Steven Burton; Peter C Gerszten; Xinxin Dong; Gregory J Gagnon; Annette Quinn; Fraser Henderson
Journal:  J Neurosurg Spine       Date:  2012-05-11

Review 9.  Dose tolerance limits and dose volume histogram evaluation for stereotactic body radiotherapy.

Authors:  Jimm Grimm; Tamara LaCouture; Raymond Croce; Inhwan Yeo; Yunping Zhu; Jinyu Xue
Journal:  J Appl Clin Med Phys       Date:  2011-02-08       Impact factor: 2.243

10.  CyberKnife robotic spinal radiosurgery in prone position: dosimetric advantage due to posterior radiation access?

Authors:  Christoph Fürweger; Christian Drexler; Alexander Muacevic; Berndt Wowra; Erik C de Klerck; Mischa S Hoogeman
Journal:  J Appl Clin Med Phys       Date:  2014-07-08       Impact factor: 2.102

View more
  13 in total

1.  Direct dose correlation of MRI morphologic alterations of healthy liver tissue after robotic liver SBRT.

Authors:  Judit Boda-Heggemann; Anika Jahnke; Mark K H Chan; Leila S Ghaderi Ardekani; Peter Hunold; Jost Philipp Schäfer; Stefan Huttenlocher; Stefan Wurster; Dirk Rades; Guido Hildebrandt; Frank Lohr; Jürgen Dunst; Frederik Wenz; Oliver Blanck
Journal:  Strahlenther Onkol       Date:  2018-02-05       Impact factor: 3.621

2.  SBRT planning for spinal metastasis: indications from a large multicentric study.

Authors:  Marco Esposito; Laura Masi; Margherita Zani; Raffaela Doro; David Fedele; Cristina Garibaldi; Stefania Clemente; Christian Fiandra; Francesca Romana Giglioli; Carmelo Marino; Laura Orsingher; Serenella Russo; Michele Stasi; Lidia Strigari; Elena Villaggi; Pietro Mancosu
Journal:  Strahlenther Onkol       Date:  2018-10-23       Impact factor: 3.621

3.  Breathing-motion-compensated robotic guided stereotactic body radiation therapy : Patterns of failure analysis.

Authors:  Susanne Stera; Panagiotis Balermpas; Mark K H Chan; Stefan Huttenlocher; Stefan Wurster; Christian Keller; Detlef Imhoff; Dirk Rades; Jürgen Dunst; Claus Rödel; Guido Hildebrandt; Oliver Blanck
Journal:  Strahlenther Onkol       Date:  2017-09-05       Impact factor: 3.621

4.  Treatment planning for spinal radiosurgery : A competitive multiplatform benchmark challenge.

Authors:  Christos Moustakis; Mark K H Chan; Jinkoo Kim; Joakim Nilsson; Alanah Bergman; Tewfik J Bichay; Isabel Palazon Cano; Savino Cilla; Francesco Deodato; Raffaela Doro; Jürgen Dunst; Hans Theodor Eich; Pierre Fau; Ming Fong; Uwe Haverkamp; Simon Heinze; Guido Hildebrandt; Detlef Imhoff; Erik de Klerck; Janett Köhn; Ulrike Lambrecht; Britta Loutfi-Krauss; Fatemeh Ebrahimi; Laura Masi; Alan H Mayville; Ante Mestrovic; Maaike Milder; Alessio G Morganti; Dirk Rades; Ulla Ramm; Claus Rödel; Frank-Andre Siebert; Wilhelm den Toom; Lei Wang; Stefan Wurster; Achim Schweikard; Scott G Soltys; Samuel Ryu; Oliver Blanck
Journal:  Strahlenther Onkol       Date:  2018-05-25       Impact factor: 3.621

5.  Planning benchmark study for SBRT of early stage NSCLC : Results of the DEGRO Working Group Stereotactic Radiotherapy.

Authors:  Christos Moustakis; Oliver Blanck; Fatemeh Ebrahimi Tazehmahalleh; Mark Ka Heng Chan; Iris Ernst; Thomas Krieger; Marciana-Nona Duma; Markus Oechsner; Ute Ganswindt; Christian Heinz; Horst Alheit; Hilbert Blank; Ursula Nestle; Rolf Wiehle; Christine Kornhuber; Christian Ostheimer; Cordula Petersen; Gerhard Pollul; Wolfgang Baus; Georg Altenstein; Eric Beckers; Katrin Jurianz; Florian Sterzing; Matthias Kretschmer; Heinrich Seegenschmiedt; Torsten Maass; Stefan Droege; Ulrich Wolf; Juergen Schoeffler; Uwe Haverkamp; Hans Theodor Eich; Matthias Guckenberger
Journal:  Strahlenther Onkol       Date:  2017-05-31       Impact factor: 3.621

6.  Treatment Planning Considerations for Robotic Guided Cardiac Radiosurgery for Atrial Fibrillation.

Authors:  Oliver Blanck; Svenja Ipsen; Mark K Chan; Ralf Bauer; Matthias Kerl; Peter Hunold; Volkmar Jacobi; Ralf Bruder; Achim Schweikard; Dirk Rades; Thomas J Vogl; Peter Kleine; Frank Bode; Jürgen Dunst
Journal:  Cureus       Date:  2016-07-20

7.  Clinical results of mean GTV dose optimized robotic guided SBRT for liver metastases.

Authors:  Nicolaus Andratschke; Alan Parys; Susanne Stadtfeld; Stefan Wurster; Stefan Huttenlocher; Detlef Imhoff; Müjdat Yildirim; Dirk Rades; Claus Michael Rödel; Jürgen Dunst; Guido Hildebrandt; Oliver Blanck
Journal:  Radiat Oncol       Date:  2016-05-28       Impact factor: 3.481

8.  Radiotoxicity in robotic radiosurgery: proposing a new quality index for optimizing the treatment planning of brain metastases.

Authors:  Alexandra Hellerbach; Klaus Luyken; Mauritius Hoevels; Andreas Gierich; Daniel Rueß; Wolfgang W Baus; Martin Kocher; Maximilian I Ruge; Harald Treuer
Journal:  Radiat Oncol       Date:  2017-08-17       Impact factor: 3.481

9.  Optimization of dose distributions of target volumes and organs at risk during stereotactic body radiation therapy for pancreatic cancer with dose-limiting auto-shells.

Authors:  Yangsen Cao; Xiaofei Zhu; Xiaoping Ju; Yongming Liu; Chunshan Yu; Yongjian Sun; Zhitao Dai; Xueling Guo; Huojun Zhang
Journal:  Radiat Oncol       Date:  2018-01-22       Impact factor: 3.481

10.  Clinical Results of Mean GTV Dose Optimized Robotic-Guided Stereotactic Body Radiation Therapy for Lung Tumors.

Authors:  Rene Baumann; Mark K H Chan; Florian Pyschny; Susanne Stera; Bettina Malzkuhn; Stefan Wurster; Stefan Huttenlocher; Marcella Szücs; Detlef Imhoff; Christian Keller; Panagiotis Balermpas; Dirk Rades; Claus Rödel; Jürgen Dunst; Guido Hildebrandt; Oliver Blanck
Journal:  Front Oncol       Date:  2018-05-17       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.